Full-Time

Group Manager

Quality Personnel & Training Management

Posted on 9/24/2025

Deadline 10/31/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

No salary listed

Visakhapatnam, Andhra Pradesh, India

In Person

Category
Medical, Clinical & Veterinary (5)
, , , ,
Requirements
  • Expert in communication and presentation of technical content
  • Expert in developing training programs such as ‘Train the Trainer.’
  • Understanding of facilitated learning modalities/ methodologies.
  • Understanding of the risk-based approach to training design
  • Awareness of training theory, learning styles, and instructional design
  • Skilled in Training design and delivery methods
  • Understanding of importance of GMP/GDP training in a pharmaceutical manufacturing environment
  • 12-15 years of experience spanning Quality Assurance or Manufacturing function /Training & Technical Skill development /Research & Development or other experience in pharmaceutical environment.
Responsibilities
  • Ensures the appropriate process for managing CVs and JDs is followed at site for employees performing GMP/GDP activities and those responsible for quality GMP/GDP decisions require JD/CVs
  • Functions as a curriculum owner for their process and execute periodic curriculum content review.
  • Reviews the risk-based approach for completeness and checks if chosen training and/or evaluation methods are aligned with the training modality.
  • Works closely with other Process Owners and SMEs for Training Risk Analysis (TRA) and Learning Needs Assessment (LNA).
  • Works with the learning specialists and people leaders to determine curricula structure and learning plan and ensures (global) curricula are assigned to local role holders.
  • Ensures that all employees have an up-to-date learning plan as per job specific role. This is in collaboration with Process Owners to ensure the right curricula are assigned to the right roles.
  • Maintains Oversight of the orientation training and Job specific learning plan assignment for new colleagues and new contingent workers.
  • Accountable for overseeing the process for Training After Long-Term Absence from Role.
  • Responsible for developing and establishing a train-the-trainer curriculum (e.g., TTT program) at site.
  • Ensure an effective training administration process with adequate resources.
  • Ensure an effective and appropriate process for the management of waivers and substitutes.
  • Ensures training materials are stored and controlled in the local document repository/content server.
  • Oversees and monitors PDOCS activities associated with SOP, SOJT and other training materials revision.
  • Measures and reports on key performance metrics defined globally and aligns to established targets. Determines improvement actions as needed.
  • Reports quality specific performance metrics for training to Site Quality Review Teams (SQRTs).
  • Responsible for monitoring overdue trainings at site.
  • Represents the Personnel and Training Management system during audits.
  • For regulatory / Board of Health (BOH) audits: Partners with business operations to complete preparation and inspection readiness activities to ensure adherence to current P&TM global SOPs and global/local work instructions (WIs); Liaises with the GPO P&TM to discuss risk and develop necessary CAPA(s) for observation(s), as needed.
  • Ensures the BCP process is sustained during an outage.
  • Maintains SASO (site administration access) in the PLA.
  • Be vigilant for potential actions or behaviors that could result in breaches of GMP compliance or Data Integrity principles.
  • Engages with Executive Sponsor and key partners to enable training strategy.
  • Supports the Global Learning Team/Training CoE with development of GMP/GDP process curricula and instructionally sound training materials.
Desired Qualifications
  • Expertise in content development
  • Technical writing skills
  • Knowledge of e -learning
  • Expertise in developing ‘Fit of Purpose’ training curricula.
  • Must have excellent content research & content editing skills.
  • Conceptual knowledge of pharmaceutical industry and related subject matter expertise.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer medicines grew 22% operationally in Q1 2026, led by Padcev up 39% and Lorbrena up 32%.
  • VYNDAMAX patent extended to 2031 secures 75% US prescription share in cardiology.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma use against J&J and BMS competitors.

What critics are saying

  • Eliquis patent expiry in 2026 triggers generic entry, eroding $17B peak cardiology sales.
  • Ibrance loses exclusivity in 2027, unleashing generics that destroy $5B breast cancer revenue.
  • Rigel deal forfeits Pfizer's Veppanu royalties, ceding 50-70% of breast cancer peak sales.

What makes Pfizer unique

  • Pfizer pioneered VEPPANU, FDA-approved first PROTAC therapy for ESR1-mutated breast cancer in May 2026.
  • Seagen acquisition doubled Pfizer's ADC trials across bladder, breast, lung, and colorectal cancers.
  • Flatiron Health collaboration since 2014 integrates real-world data for NSCLC and CRC development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE